Home
Fitness
Weight Management
Eating Disorders
Exercise
Video
FitnessForU
Fitness blog offering information on staying fit and in shape
News
Featured
Great Offers
Posts
Comments
You are here:
Home
/
News
/ US FDA approves Pfizer’s Inlyta for kidney cancer
US FDA approves Pfizer’s Inlyta for kidney cancer
January 27, 2012
By
Health News From Reuters
Related posts:
FDA approves Pfizer’s Inlyta for kidney cancer
FDA staff find small subset behind Inlyta effect
FDA panel backs Pfizer’s drug for kidney cancer
FDA panel backs Pfizer’s drug for kidney cancer
Pfizer cancer drug effect may be limited: FDA staff
Filed Under:
News
Tagged With:
health & fitness
,
News
Sponsor
Latest Posts
Alcoholism not uncommon among surgeons
Vivus asks U.S. experts to back its obesity drug
Altria seeks to tap wide-ranging tobacco users
Judge to rule if pharmacies must sell "Plan B" pills
Supreme Court sends back California Medicaid cuts case
More troops on smokeless tobacco after deployment
Gender "non-conformity" tied to abuse: study
Johnson & Johnson CEO Weldon to step down in April
Debate over conscience in the workplace intensifies
Johnson & Johnson CEO Weldon to step down in April
Gender "non-conformity" tied to abuse in kids
Many "mistakes" found in newbie-doctors’ resumes
Heart attack with no chest pain more likely in women
Combined vaccine tied to fever-related seizures
Catgories
Select Category
Binge Eating Treatment
Causes for Eating Disorders
Cycling
DVD on Offer
Eating Disorders
Equipment
Exercise
Featured
Fitness
Fitness Equipment
General
Great Offers
Kids Fitness
News
Q&A
Running
Solutions to Eating Disorders
Types of Eating Disorder
Video
Weight Management
Workouts
Archives
Select Month
February 2012
January 2012
December 2011
November 2011
October 2011
September 2011
August 2011
July 2011
June 2011
May 2011
April 2011
March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
Comments